Deakin home > Deakin University Library > Deakin Research Online > From neuroprogression to neuroprotection : implications for clinical care

From neuroprogression to neuroprotection : implications for clinical care

Berk, Michael, Conus, Philippe, Kapczinski, Flávio, Andreazza, Ana C, Yücel, Murat, Wood, Stephen J, Pantelis, Christos, Malhi, Gin S, Dodd, Seetal, Bechdolf, Andreas, Amminger, G Paul, Hickie, Ian B and McGorry, Patrick D 2010, From neuroprogression to neuroprotection : implications for clinical care, Medical journal of australia, vol. 193, no. 4, pp. S36-S40.

Attached Files (Some files may be inaccessible until you login with your Deakin Research Online credentials)
Name Description MIMEType Size Downloads

Title From neuroprogression to neuroprotection : implications for clinical care
Author(s) Berk, Michael
Conus, Philippe
Kapczinski, Flávio
Andreazza, Ana C
Yücel, Murat
Wood, Stephen J
Pantelis, Christos
Malhi, Gin S
Dodd, Seetal
Bechdolf, Andreas
Amminger, G Paul
Hickie, Ian B
McGorry, Patrick D
Journal name Medical journal of australia
Volume number 193
Issue number 4
Start page S36
End page S40
Publisher Australasian Medical Publishing Company
Place of publication Strawberry Hills, N.S.W.
Publication date 2010-08-16
ISSN 0025-729X
Summary • Bipolar disorder follows a staged trajectory in which persistence of illness is associated with a number of clinical features such as progressive shortening of the inter-episode interval and decreased probability of treatment response.

• This neuroprogressive clinical process is reflected by both progressive neuroanatomical changes and evidence of cognitive decline.

• The biochemical foundation of this process appears to incorporate changes in inflammatory cytokines, cortisone, neurotrophins and oxidative stress. There is a growing body of evidence to suggest that these markers may differ between the early and late stages of the disorder.

• The presence of a series of tangible targets raises the spectre of development of rational neuroprotective strategies, involving judicious use of current therapies and novel agents. Most of the currently used mood stabilisers share effects on oxidative stress and neurotrophins, while novel potentially neuroprotective agents are being developed. These developments need to be combined with service initiatives to maximise the opportunities for early diagnosis and intervention.
Language eng
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2010, Australasian Medical Publishing Company
Persistent URL http://hdl.handle.net/10536/DRO/DU:30035523

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in Deakin Research Online is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 25 times in Scopus
Access Statistics: 46 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 22 Jun 2011, 12:32:44 EST